CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Friday reported a loss of $56.1 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of 55 cents per share.

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 61 cents per share.

The biopharmaceutical company posted revenue of $3.6 million in the period, falling short of Street forecasts. Four analysts surveyed by Zacks expected $6 million.

Epizyme shares have declined 45% since the beginning of the year. The stock has dropped 8% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EPZM at https://www.zacks.com/ap/EPZM

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News